Literature DB >> 8980763

In vitro activity of BAY 12-8039, a new fluoroquinolone.

J M Woodcock1, J M Andrews, F J Boswell, N P Brenwald, R Wise.   

Abstract

The in vitro activity of BAY 12-8039, a new fluoroquinolone, was studied in comparison with those of ciprofloxacin, trovafloxacin (CP 99,219), cefpodoxime, and amoxicillin-clavulanate against gram-negative, gram-positive, and anaerobic bacteria. Its activity against mycobacteria and chlamydia was also investigated. BAY 12-8039 was active against members of the family Enterobacteriaceae (MIC at which 90% of strains tested were inhibited [MIC90S] < or = 1 microgram/ml, except for Serratia spp. MIC90 2 microgram/ml), Neisseria spp. (MIC90S, 0.015 microgram/ml), Haemophilus influenzae (MIC90, 0.03 microgram/ml), and Moraxella catarrhalis (MIC90, 0.12 micrgram/ml), and these results were comparable to those obtained for ciprofloxacin and trovafloxacin. Against Pseudomonas aeruginosa, the quinolones were more active than the beta-lactam agents but BAY 12-8039 was less active than ciprofloxacin. Strains of Stenotrophomonas maltophilia were fourfold more susceptible to BAY 12-8039 and trovafloxacin (MIC90S, 2 micrograms/ml) than to ciprofloxacin. BAY 12-8039 was as active as trovafloxacin but more active than ciprofloxacin against Streptococcus pneumoniae (MIC90, 0.25 microgram/ml) and methicillin-susceptible Staphylococcus auerus (MIC90S, 0.12 micrograms/ml). The activity of BAY 12-8039 against methicillin-resistant S. aureus (MIC90, 2 micrograms/ml) was lower than that against methicillin-susceptible strains. BAY 12-8039 was active against anaerobes (MIC90S < or = 2 micrograms/ml), being three- to fourfold more active against Bacteroides fragilis, Prevotella spp., and Clostridium difficile than was ciprofloxacin. Against Mycobacterium tuberculosis, BAY 12-8039 exhibited activity comparable to that of rifampin (MICs < or = 0.5 micrograms/ml). Against Chlamydia trachomatis and Chlamydia pneumoniae BAY 12-8039 was more active (MICs < or = 0.12 microgram/ml) than either ciprofloxacin or erythromycin and exhibited a greater lethal effect than either to these two agents. The protein binding of BAY 12-8039 was determined at 1 and 5 micrograms/ml as 30 and 26.4%, respectively. The presence of human serum (at 20 or 70%) had no marked effect on the in vitro activity of BAY 12-8039.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8980763      PMCID: PMC163668     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.

Authors:  J M Webberley; R S Matthews; J M Andrews; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

Authors:  E Wakabayashi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.

Authors:  J Child; J Andrews; F Boswell; N Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

  7 in total
  66 in total

1.  Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Quinolones in sexually transmitted diseases: state of the art.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1999       Impact factor: 9.546

3.  Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration.

Authors:  R Wise; J M Andrews; G Marshall; G Hartman
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.

Authors:  J Lettieri; R Vargas; V Agarwal; P Liu
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.

Authors:  G Prats; C Roig; E Miró; F Navarro; B Mirelis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-04-19       Impact factor: 3.267

7.  Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors:  Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

9.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.

Authors:  V Rodriguez-Cerrato; C C McCoig; I C Michelow; F Ghaffar; H S Jafri; R D Hardy; C Patel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.